Related Experiment Videos
Severe hypomagnesaemia with tetany following ESHAP protocol
1FRCPath Consultant Haematologist Doncaster Royal Infirmary Thorne Road Doncaster, DN2 5LY United Kingdom. gautam.majumdar@dbh.nhs.uk
BMC Blood Disorders
|January 22, 2002
Summary
The ESHAP chemotherapy protocol can cause severe hypomagnesaemia (low magnesium levels) and tetany in patients with Non-Hodgkin
Area of Science:
- Oncology
- Hematology
- Clinical Chemistry
Background:
- A patient with B-cell Non-Hodgkin's Lymphoma experienced severe hypomagnesaemia and tetany following ESHAP chemotherapy.
- This adverse event prompted an investigation into the incidence and severity of hypomagnesaemia during ESHAP treatment.
Purpose of the Study:
- To assess the incidence and severity of hypomagnesaemia in patients undergoing ESHAP protocol treatment.
- To determine the temporal relationship between ESHAP chemotherapy and the development of hypomagnesaemia.
Main Methods:
- Monitoring of serum magnesium levels in three patients treated with the ESHAP protocol.
- Clinical observation for symptoms of hypomagnesaemia and tetany.
Main Results:
- All three monitored patients developed significant hypomagnesaemia.
- Hypomagnesaemia typically occurred two to three weeks after chemotherapy courses.
- Intravenous magnesium infusion was required for all affected patients.
Conclusions:
- The ESHAP protocol is frequently associated with significant hypomagnesaemia.
- Serum magnesium levels require monitoring throughout the ESHAP treatment period to manage potential complications.